Scholarlink

Background <p>5-Aminolevulinic acid (5-ALA) reportedly improves overactive bladder (OAB) symptoms by reducing reactive oxygen species derived from vascular endothelial cells to protect vascular function and enhance bladder blood flow and by inhibiting bladder C-fiber activity. This double-blind, randomized controlled trial aimed to evaluate the efficacy and safety of 5-ALA in participants with OAB.</p> Methods <p>This randomized, prospective study classified the participants into the 5-ALA and placebo groups. The 5-ALA group received oral 5-ALA phosphate at 150&#xa0;mg/day for 12&#xa0;weeks. The efficacy of 5-ALA was determined by assessing the changes in the Overactive Bladder Symptom Score (OABSS) and the Overactive Bladder Questionnaire Short Form from baseline to weeks 4 and 12 after treatment initiation, as well as the post-void residual urine volume. Regarding safety, we evaluated participants’ blood pressure and adverse events.</p> Results <p>This study enrolled and randomized 49 participants, with 23 in the 5-ALA group and 26 in the placebo group. Ultimately, 47 participants completed the study (21 and 26 in the 5-ALA and placebo groups, respectively). From baseline to week 12, OABSS significantly decreased from 8.81 to 6.52 (− 2.29) in the 5-ALA group and from 8.54 to 6.35 (− 2.35) in the placebo group (both: <i>p</i> = 0.008). However, no significant difference was noted between the two groups at week 12 (<i>p</i> = 0.956). Using a mixed model for repeated measures with a random intercept, the model-adjusted between-group difference in the change from baseline to week 12 in the OABSS between the 5-ALA and placebo groups was 0.06 points (95% confidence interval, − 1.63 to 1.75; <i>p</i> = 0.944).</p> Conclusions <p>This study found no significant improvement in OAB symptoms with 5-ALA administration. Nevertheless, given that no previous double-blind, randomized controlled trial has assessed 5-ALA’s efficacy in patients with OAB, this study holds important value as a pilot study.</p> Trial registration <p>This study was prospectively registered in the Japan Registry of Clinical Trials (jRCT); registration number: jRCTs061220050; registration date: [August 29, 2022].</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oral 5‑aminolevulinic acid for overactive bladder: a double‑blind, randomized, placebo‑controlled pilot trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月20日

查看全文
  • Satoshi Fukata,
  • Nobutaka Shimizu,
  • Takahira Kuno,
  • Rie Yoshimura,
  • Hiroki Sugimoto,
  • Ayano Kawaguchi,
  • Yoshitaka Kurano,
  • Daigo Takemori,
  • Shinkuro Yamamoto,
  • Taeko Nishioka,
  • Natsuko Nakamura,
  • Hajime Kuroiwa,
  • Hiroko Iijima,
  • Takashi Karashima,
  • Keiji Inoue

摘要

Background

5-Aminolevulinic acid (5-ALA) reportedly improves overactive bladder (OAB) symptoms by reducing reactive oxygen species derived from vascular endothelial cells to protect vascular function and enhance bladder blood flow and by inhibiting bladder C-fiber activity. This double-blind, randomized controlled trial aimed to evaluate the efficacy and safety of 5-ALA in participants with OAB.

Methods

This randomized, prospective study classified the participants into the 5-ALA and placebo groups. The 5-ALA group received oral 5-ALA phosphate at 150 mg/day for 12 weeks. The efficacy of 5-ALA was determined by assessing the changes in the Overactive Bladder Symptom Score (OABSS) and the Overactive Bladder Questionnaire Short Form from baseline to weeks 4 and 12 after treatment initiation, as well as the post-void residual urine volume. Regarding safety, we evaluated participants’ blood pressure and adverse events.

Results

This study enrolled and randomized 49 participants, with 23 in the 5-ALA group and 26 in the placebo group. Ultimately, 47 participants completed the study (21 and 26 in the 5-ALA and placebo groups, respectively). From baseline to week 12, OABSS significantly decreased from 8.81 to 6.52 (− 2.29) in the 5-ALA group and from 8.54 to 6.35 (− 2.35) in the placebo group (both: p = 0.008). However, no significant difference was noted between the two groups at week 12 (p = 0.956). Using a mixed model for repeated measures with a random intercept, the model-adjusted between-group difference in the change from baseline to week 12 in the OABSS between the 5-ALA and placebo groups was 0.06 points (95% confidence interval, − 1.63 to 1.75; p = 0.944).

Conclusions

This study found no significant improvement in OAB symptoms with 5-ALA administration. Nevertheless, given that no previous double-blind, randomized controlled trial has assessed 5-ALA’s efficacy in patients with OAB, this study holds important value as a pilot study.

Trial registration

This study was prospectively registered in the Japan Registry of Clinical Trials (jRCT); registration number: jRCTs061220050; registration date: [August 29, 2022].